Please ensure Javascript is enabled for purposes of website accessibility

2 Best Biotech Stocks to Buy in August

By Alex Carchidi – Aug 9, 2020 at 7:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These two stocks are probably undervalued, but that won’t last forever.

Biotech stocks are often prone to highly inflated or highly deflated prices stemming from hyped news cycles. Between difficult-to-interpret news about a company's clinical-trial results and the sheer length of the drug-development cycle, some stocks spend months languishing because of the market's ire. But for investors with a long-term outlook, a biotech stock taking an unwarranted beating could be a great opportunity to buy in at a discount.

Both of the stocks I'll discuss today have had a rough year so far, performing worse than the market by a substantial margin. Furthermore, both lost out to the market over the last three years, potentially making conservative investors anxious. Despite their recent difficulties, however, these stocks have a few key value-investment factors in their favor, and there's reason to believe that the market will catch on soon enough.

A microscope objective is superimposed on an electrocardiogram readout.

Image source: Getty Images.

Alexion Pharmaceuticals

Alexion Pharmaceuticals (ALXN) produces a handful of niche drugs for rare diseases like hypophosphatasia (a genetic disorder affecting growth of bones and teeth), meaning that the markets it competes in are inherently small. This may dissuade some investors, but a closer look at the company's finances indicates that the company is making the most of its position.

In particular, free cash flow has risen by 172.5% in the last few years, suggesting that the company is gaining financial momentum. Similarly, Alexion's normalized trailing-12-month (TTM) diluted earnings per share (EPS) have grown by more than 260% over the past three years, and its TTM revenue number has increased by 59.5% in the same period.

There's also evidence that points to Alexion as a value stock. Its TTM price-to-earnings (P/E) ratio sits at 9.9, significantly lower than the biotech industry's average of 77.6. This means that new investors will pay less for each fraction of the company's earnings than they might with other industry stocks. Finally, Alexion's price-to-book value (P/B) ratio clocked in at 2.2 in the most recent quarter, compared with the industry average of 6.2, which indicates that each share is cheaper than average relative to the company's assets. As these ratios rise to reach the rest of the industry, it will be a strong sign that the stock is becoming less of a bargain.

SPY Chart

SPY data by YCharts

Innoviva

With a market cap of $1.4 billion, Innoviva (INVA -2.02%) is much smaller than Alexion, and it's also in a different line of business. In short, Innoviva curates royalty-bearing assets rather than developing or manufacturing drugs of its own. Most of the company's royalty rights are for respiratory drugs developed by GlaxoSmithKline (GSK 0.24%).

Thanks to its careful cultivation of new royalty rights, its TTM revenue has risen 56.5% since 2017, and its free cash flow was up by 141.5%. These positive results belie even more favorable data, including year-over-year quarterly earnings growth of 103.6%. So why hasn't the stock beaten the market, and why is it so cheap?

There are two factors that might be to blame. First, the stock's dividend peaked in 2015 before sharply tapering to zero, which might have irritated shareholders. Second, the company's earnings contracted during 2018.

But with an aggressive P/B ratio of 3 in the most recent quarter and a trailing 12-month P/E ratio of 6.7, Innoviva is still a bargain in the context of the biotech industry's averages. Given that this year saw its trailing P/E rise for the first time since before 2016, the market may soon notice the company's strong fundamentals and spur price growth once again.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN
Innoviva, Inc. Stock Quote
Innoviva, Inc.
INVA
$11.62 (-2.02%) $0.24
GSK Stock Quote
GSK
GSK
$29.43 (0.24%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.